Top

Published in:

01-10-2009

Obesity, Gut Hormones, and Bariatric Surgery

Authors: Dimitrios J. Pournaras, Carel W. le Roux

Published in: World Journal of Surgery | Issue 10/2009

Abstract

Obesity is becoming the healthcare epidemic of this century. Bariatric surgery is the only effective treatment for morbid obesity. Gut hormones are key players in the metabolic mechanisms causing obesity. In this review we explore the role of these hormones as facilitators of appetite control and weight loss after bariatric surgery, and we describe the now established gut–brain axis.

Sjöström L, Narbro K, Sjöström CD et al (2007) Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:741–752

Buchwald H, Avidor Y, Braunwald E et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737PubMedCrossRef

Morton GJ, Cummings DE, Baskin DG et al (2006) Central nervous system control of food intake and body weight. Nature 443:289–295PubMedCrossRef

Flier JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337–350PubMedCrossRef

Schwartz MW, Woods SC, Seeley RJ et al (2003) Is the energy homeostasis system inherently biased toward weight gain? Diabetes 52:232–238PubMedCrossRef

Ahima RS, Prabakaran D, Mantzoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252PubMedCrossRef

Leibel RL, Rosenbaum M, Hirsch J (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332:621–628PubMedCrossRef

Ellacott KL, Halatchev IG, Cone RD (2006) Interactions between gut peptides and the central melanocortin system in the regulation of energy homeostasis. Peptides 27:340–349PubMedCrossRef

Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117:13–23PubMedCrossRef

10.

Neary NM, Small CJ, Druce MR et al (2005) Peptide YY3–36 and glucagon-like peptide-17–36 inhibit food intake additively. Endocrinology 146:5120–5127PubMedCrossRef

11.

Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157PubMedCrossRef

12.

Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161–171PubMedCrossRef

13.

le Roux CW, Aylwin SJ, Batterham RL et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114PubMedCrossRef

14.

le Roux CW, Welbourn R, Werling M et al (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780–785PubMedCrossRef

15.

Näslund E, Backman L, Holst JJ et al (1998) Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8:253–260PubMedCrossRef

16.

Laferrère B, Teixeira J, McGinty J et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. Clin Endocrinol Metab 93:2479–2485CrossRef

17.

Adrian TE, Ferri GL, Bacarese-Hamilton AJ et al (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed

18.

Oesch S, Rüegg C, Fischer B et al (2006) Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav 87:903–910PubMedCrossRef

19.

Gehlert DR (1998) Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implications. Proc Soc Exp Biol Med 218:7–22PubMed

20.

Deng X, Wood PG, Sved AF et al (2001) The area postrema lesions alter the inhibitory effects of peripherally infused pancreatic polypeptide on pancreatic secretion. Brain Res 902:18–29PubMedCrossRef

21.

Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef

22.

Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349:941–948PubMedCrossRef

23.

le Roux CW, Batterham RL, Aylwin SJ et al (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147:3–8PubMedCrossRef

24.

Korner J, Bessler M, Cirilo LJ et al (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359–365PubMedCrossRef

25.

Korner J, Inabnet W, Conwell IM et al (2006) Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity 14:1553–1561PubMedCrossRef

26.

Borg CM, le Roux CW, Ghatei MA et al (2006) Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93:210–215PubMedCrossRef

27.

Alvarez Bartolomé M, Borque M, Martinez-Sarmiento J et al (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12:324–327PubMedCrossRef

28.

Karamanakos SN, Vagenas K, Kalfarentzos F et al (2008) Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 247:401–407PubMedCrossRef

29.

Chelikani PK, Haver AC, Reidelberger RD (2006) Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY (3–36) on food intake and gastric emptying in rats. Diabetes 55:3038–3046PubMedCrossRef

30.

Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef

31.

Frühbeck G, Diez Caballero A, Gil MJ (2004) Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 350:308–309PubMedCrossRef

32.

Wren AM, Small CJ, Abbott CR et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547PubMedCrossRef

33.

Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMedCrossRef

34.

Callahan HS, Cummings DE, Pepe MS et al (2004) Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 89:1319–1324PubMedCrossRef

35.

Cummings DE, Purnell JQ, Frayo RS et al (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714–1719PubMedCrossRef

36.

Cummings DE, Weigle DS, Frayo RS et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630PubMedCrossRef

37.

le Roux CW, Patterson M, Vincent RP et al (2005) Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 90:1068–1071PubMedCrossRef

38.

Zhang JV, Ren PG, Avsian-Kretchmer O et al (2005) Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science 310:996–999PubMedCrossRef

39.

Jackson VR, Nothacker HP, Civelli O (2006) GPR39 receptor expression in the mouse brain. Neuroreport 17:813–816PubMedCrossRef

40.

Gourcerol G, St-Pierre DH, Taché Y (2007) Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 141:1–7PubMedCrossRef

41.

Geloneze B, Tambascia MA, Pilla VF et al (2003) Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 13:17–22PubMedCrossRef

42.

Morínigo R, Casamitjana R, Moizé V et al (2004) Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res 12:1108–1116PubMedCrossRef

43.

Faraj M, Havel PJ, Phélis S et al (2003) Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88:1594–1602PubMedCrossRef

44.

Stoeckli R, Chanda R, Langer I et al (2004) Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 12:346–350PubMedCrossRef

45.

Vendrell J, Broch M, Vilarrasa N et al (2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12:962–971PubMedCrossRef

46.

Holdstock C, Engström BE, Ohrvall M et al (2003) Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88:3177–3183PubMedCrossRef

47.

Lin E, Gletsu N, Fugate K et al (2004) The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg 139:780–784PubMedCrossRef

48.

le Roux CW, Neary NM, Halsey TJ et al (2005) Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 90:4521–4524PubMedCrossRef

49.

Sundbom M, Holdstock C, Engström BE et al (2007) Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 17:304–310PubMedCrossRef

50.

Pories WJ (2008) Ghrelin? Yes, it is spelled correctly. Ann Surg 247:408–410PubMedCrossRef

51.

McLaughlin T, Abbasi F, Lamendola C et al (2004) Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 89:1630–1635PubMedCrossRef

52.

Adami GF, Cordera R, Marinari G et al (2003) Plasma ghrelin concentration in the short-term following biliopancreatic diversion. Obes Surg 13:889–892PubMedCrossRef

53.

Parker BA, Doran S, Wishart J et al (2005) Effects of small intestinal and gastric glucose administration on the suppression of plasma ghrelin concentrations in healthy older men and women. Clin Endocrinol (Oxf) 62:539–546CrossRef

54.

Schindler K, Prager G, Ballaban T et al (2004) Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Invest 34:549–554PubMedCrossRef

55.

Nijhuis J, van Dielen FM, Buurman WA et al (2004) Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 14:783–787PubMedCrossRef

56.

Leonetti F, Silecchia G, Iacobellis G et al (2003) Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 88:4227–4231PubMedCrossRef

57.

Melissas J, Daskalakis M, Koukouraki S et al (2008) Sleeve gastrectomy—a “food limiting” operation. Obes Surg 18:1251–1256PubMedCrossRef

58.

Langer FB, Reza Hoda MA, Bohdjalian A et al (2005) Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 15:1024–1029PubMedCrossRef

59.

Cohen R, Uzzan B, Bihan H et al (2005) Ghrelin levels and sleeve gastrectomy in super-super-obesity. Obes Surg 15:1501–1502PubMedCrossRef

60.

Aylwin S (2005) Gastrointestinal surgery and gut hormones. Curr Opin Endocrinol Diabetes 12:89–98CrossRef

61.

Chandra R, Liddle RA (2007) Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 14:63–67PubMed

62.

Kellum JM, Kuemmerle JF, O’Dorisio TM et al (1990) Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 211:763–770 discussion 770–771PubMedCrossRef

63.

Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCrossRef

64.

Foschi D, Corsi F, Pisoni L et al (2004) Plasma cholecystokinin levels after vertical banded gastroplasty: effects of an acidified meal. Obes Surg 14:644–647PubMedCrossRef

65.

Sørensen TI, Lauritsen KB, Holst JJ et al (1983) Gut and pancreatic hormones after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Digestion 26:137–145PubMedCrossRef

66.

Sarson DL, Scopinaro N, Bloom SR (1981) Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5:471–480PubMed

67.

Cohen MA, Ellis SM, Le Roux CW et al (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696–4701PubMedCrossRef

68.

Wynne K, Park AJ, Small CJ et al (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:2390–2395PubMedCrossRef

69.

Batterham RL, le Roux CW, Cohen MA et al (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989–3992PubMedCrossRef

Title: Obesity, Gut Hormones, and Bariatric Surgery
Authors: Dimitrios J. Pournaras
Carel W. le Roux
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 10/2009
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-009-0080-9

2024 ASCO Annual Meeting

Springer Medicine

Obesity, Gut Hormones, and Bariatric Surgery

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Cardiovascular Risk in Patients with Nonfunctional Adrenal Incidentaloma: Myth or Reality?

Vagal Nerve Function in Obesity: Therapeutic Implications

Metastatic Lymph Node Ratio: A New Staging System for Gastric Cancer

Prevalence of Hypothyroidism in Benign Breast Disorders and Effect of Thyroxine Replacement on the Clinical Outcome

Anatomy-Specific Pancreatic Stump Management to Reduce the Risk of Pancreatic Fistula After Pancreatic Head Resection

The Impact of Launching Surgery at the District Level in Niger